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Abstract
Introduction: Angiogenesis has been shown to be necessary for the development and progression of solid tumours. VEGF
is one of the crucial pro-angiogenic cytokines produced by the cells of many of the tumours examined, including various
types of anterior pituitary adenomas. Angiotensin II (Ang II) is known to regulate the expression of VEGF in a variety of
tissues both in the physiological and pathological conditions. Moreover, an association of the renin-angiotensin system (RAS)
with oestrogen-induced vascular changes during the development of rat pituitary PRL-secreting adenoma has already been
demonstrated.
The aim of the study was to determine the in vitro effects of angiotensin peptides (Ang II, Ang III and Ang IV) on the
secretion of VEGF in two anterior pituitary adenoma cell cultures: the culture of the rat pituitary lactosomatotrope tumour
cell line (GH3) and the primary culture of rat PRL-secreting tumour induced by diethylstilbestrol (DES).
Material and methods: GH3 and prolactinoma cells were cultured in an F-10 and an F-12 medium respectively and then
placed into 24 multiwell plates (105 of GH3 cells/well and 106 of rat prolactinoma cells/well). After 12 hours of preincubation
the cells underwent 24-hour treatment with Ang II, Ang III or Ang IV at final concentrations of 10–12, 10–10, 10–8 or 10–6M and,
in the case of the GH3 cells, combined treatment with Ang II (10–10M) and specific AT1 or AT2 receptor antagonist (losartan
or PD123319 respectively at a concentration of 10–8 or 10–7 M). The concentration of VEGF in the supernatant collected was
determined using specific ELISA assay kits. Statistical evaluation was performed using Student’s test and analysis of va-
riance (ANOVA). Differences were considered significant if p < 0.05.
Results: The incubation of both GH3 cells and rat adenoma cells with Ang II, Ang III or Ang IV at concentrations of 10–12 –
–10–8M resulted in a significant increase in VEGF concentration in the culture medium. Exposure of GH3 cells to Ang III or
Ang IV at concentrations of 10-6M led to a significant inhibition of cytokine release, and Pearson’s correlation curve showed
a tendency for Ang II at concentrations of more than 10–6M to inhibit VEGF secretion in primary prolactinoma cell culture.
The stimulatory influence of Ang II on VEGF secretion in GH3 cell culture was negated by losartan or by PD123319 in both
concentrations tested.
Conclusions: Ang II, Ang III and Ang IV affect the secretion of VEGF in cultures of the rat lactosomatotrope GH3 cell line
and primary rat prolactinoma cells. Both AT1 and AT2 receptors mediate the stimulatory action of Ang II on the cytokine
release in GH3 cell culture. The mechanism of the observed anti-angiogenic effects of angiotensin peptides remains une-
xplained.
(Pol J Endocrinol 2007; 58 (6): 478–486)
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Streszczenie
Wstęp: Angiogeneza to niezbędny etap w procesie formowania i progresji guzów litych. VEGF należy do kluczowych
cytokin proangiogennych, syntetyzowanych przez komórki wielu badanych dotychczas guzów, włączając różne typy gru-
czolaków przysadki. Angiotensyna II należy do czynników regulujących ekspresję VEGF w różnych tkankach, zarówno
w warunkach fizjologii, jak i patologii. Co więcej, udowodniono związek układu renina–angiotensyna (układu RA) z indukowa-
nym estrogenami wzrostem naczyń w procesie formowania doświadczalnego guza prolaktynowego przysadki u szczura.
Celem pracy było zbadanie wpływu peptydów angiotensynowych (ang II, ang III i ang IV) na wydzielanie VEGF w dwóch
hodowlach komórkowych gruczolaka przysadki: w ciągłej hodowli linii guza laktosomatotropowego GH3 oraz w pierwot-
nej hodowli indukowanego dietylstilbestrolem (DES) guza prolaktynowego szczura.
Materiał i metody: Komórki GH3 oraz komórki prolactinoma hodowano odpowiednio w mediach F-10 i F-12, a następnie
rozsiewano do studzienek 24-dołkowych płytek hodowlanych (105 komórek GH3 na studzienkę i 106 komórek gruczolaka
na studzienkę). Po 12 godzinach preinkubacji komórki inkubowano przez 24 godziny w obecności ang II, ang III lub ang IV
w stężeniach 10–12, 10–10, 10–8 lub 10–6M lub, w przypadku komórek GH3, w obecności ang II (10–10M) w połączeniu ze specy-
ficznym antagonistą receptora AT1 losartanem lub receptora AT2 — PD123319 w stężeniach 10–8 lub 10–7M. Stężenie VEGF
w medium hodowlanym oznaczano, wykorzystując metodę ELISA. Analizy statystycznej dokonywano przy użyciu testu
t-Studenta oraz na podstawie analizy wariancji (ANOVA), dla poziomu istotności p < 0.05.
Wyniki: Inkubacja komórek GH3 lub komórek pierwotnej hodowli guza prolaktynowego w obecności ang II, ang III lub
ang IV w stężeniach 10–12 – 10–8M prowadziła do wzrostu stężeń VEGF w medium hodowlanym. Przeciwnie, po ekspozycji
komórek GH3 na działanie ang III lub ang IV w stężeniach 10–6M dochodziło do zahamowania wydzielania cytokiny,
a krzywa korelacji Persona wykazała dodatkowo tendencję do hamowania wydzielania VEGF w pierwotnej hodowli pro-
lactinoma przez ang II w stężeniach przekraczających 10–6M. Pobudzający wpływ ang II na sekrecję VEGF przez komórki
GH3 znoszony był zarówno przez losartan, jak i PD123319.
 Wnioski: Ang II, ang III i ang IV wpływają na wydzielanie VEGF przez komórki GH3 oraz komórki gruczolaka prolakty-
nowego szczura. Zarówno receptory AT1, jak i AT2 pośredniczą w proangiogennym efekcie ang II w hodowli GH3. Me-
chanizm obserwowanego, hamującego oddziaływania peptydów angiotensynowych na sekrecję VEGF pozostaje niewy-
jaśniony.
(Endokrynol Pol 2007; 58 (6): 478–486)
Słowa kluczowe: gruczolaki przysadki, angiotensyny, VEGF, hodowle komórkowe
Introduction
Angiogenesis is the process of formation of new blood
vessels from pre-existing vasculature [1]. Vascular en-
dothelial growth factor (VEGF) is one of the essential
pro-angiogenic cytokines. This glycoprotein is known
to be a strong specific mitogen for endothelial cells (EC)
in vitro as well as a pro-angiogenic and vascular perme-
ability-stimulating factor in vivo [2].
Neovascularisation has been shown to be crucial for
the development of solid tumours beyond a few milli-
metres and for determining further tumour progression
and spread [3]. VEGF mRNA has been shown to be up-
regulated in a variety of the tumours that have been
examined, with invariable expression in tumour cells
and, additionally, in the surrounding stroma and tu-
mour vasculature [4–7]. Nevertheless, there is still con-
troversy regarding the role of angiogenesis in pituitary
tumour formation and growth [8]. In contrast to the
results of studies on other tissues, the available data in-
dicate lower vascular densities of pituitary adenomas
compared to a normal non-tumorous gland [9–11].
However, the fundamental functional consequence of
pituitary angiogenesis may be connected with the in-
growth of blood vessels from the systemic circulation
[12–14]. The direct arterial blood supply uncouples the
tumour from the portal blood vessel system, leading the
cells to escape from hypothalamic control [15]. The im-
portance of angiogenesis for pituitary tumour develop-
ment is suggested by the growing number of experimen-
tal studies and clinical observations. A relationship has
been reported between the degree of vascularisation and
tumour invasiveness, particularly apparent in aggressi-
ve macroprolactinomas. Higher vascular densities were
found in rare pituitary carcinomas compared to benign
adenomas [8]. Increased vasculogenesis appeared during
the development of oestrogen-induced rat prolactinoma
[16]. Serum concentrations of pro-angiogenic factors, in-
cluding VEGF, were elevated in the peripheral blood of
patients with pituitary adenomas [17].
The involvement of the rennin–angiotensin system
(RAS) in the regulation of angiogenesis has already been
demonstrated by many authors. They observed angio-
tensin II (Ang II)-stimulated vessel growth in the mo-
use and rat sponge implant model of angiogenesis, de-
veloping chick chorioallantoic membrane, the cornea
and rat cremaster muscle [18–21]. Ang II was shown to
stimulate VEGF expression in human vascular smooth
muscle cells (VSMCs), cardiac endothelial cells and re-
nal mesangial cells, to promote VEGF receptor expres-
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sion in bovine retinal microcapillary endothelial cells
and retinal pericytes, and to potentiate VEGF-induced
EC growth and tube formation [22–26]. This peptide has
also been implicated in physiological angiogenesis in-
duced by electrical stimulation or exercise [27, 28]. Expe-
rimental and clinical studies have also demonstrated the
essential role of RAS in pathological angiogenesis and
its potential association with such states as atherosclero-
sis, diabetic proliferative retinopathy and nephropathy.
Treatment with angiotensin receptor blockers resulted
in the suppression of retinal neovascularisation and re-
duction of VEGF expression by podocytes in diabetic rats
[29, 30]. Feman et al. and Danser at al. revealed that the
serum and intraviteral levels of prorenin, angiotensin-
converting enzyme (ACE) and Ang II were increased in
patients with proliferative diabetic retinopathy [31, 32].
Furthermore, patients with type 1 diabetes were less li-
kely to develop proliferative diabetic retinopathy when
treated with the ACE inhibitor lisinopril [33].
Increasing lines of evidence indicate an association
between RAS and the neoangiogenesis and growth of
solid tumour [34]. With respect to the pituitary, Pawli-
kowski et al. suggest an involvement of Ang II in the
mechanism of estrogen-induced vascular changes du-
ring the development of experimental rat pituitary PRL-
secreting adenoma [35]. However, the role of angioten-
sin peptides in the regulation of the angiogenic activity
of rat pituitary adenoma cells in vitro has not been de-
termined. The purpose of our study was to assess the
influence of Ang II and its derivatives Ang III and Ang
IV on the secretion of VEGF in two cell cultures, the
culture of permanent rat lactosomatotrope tumour cell
line GH3 and the primary culture of rat PRL-secreting
adenoma. We also examined the potential association
of the effects of Ang II with two main angiotensin
receptor subtypes, the AT1 receptor and the AT2
receptor.
Material and methods
Cell cultures
GH3 cell culture
The rat lactosomatotrope cell line GH3 was obtained
using ATCC, LGC Promochem. Continuous GH3 cell
culture was maintained in culture flasks (Nunc Eas
Y Flask 25 cm2, NUNC). All the cells were grown in Ham’s
F-10 medium supplemented with 1.2 g/l Sodium Bicar-
bonate (Sigma), 100 U/ml Penicillin and 100 mg/ml
Streptomycin Solution (Sigma), 15% heat-inactivated
horse serum (Sigma) and 2.5% heat-inactivated foetal
bovine serum (FBS, Biochrom, KG) at 370C and in
a humidified atmosphere of 95% air and 5% CO2. Eve-
ry 7 days, the cells were harvested after a 2-min incuba-
tion at 370C in the presence of trypsin-EDTA (0.05 or
0.02% respectively) in Hanks balanced solution (Sigma).
The cells were washed twice in complete F-10 medium
and after the last centrifugation seeded at 1 x 105 cells in
5 ml of fresh medium.
Primary cell culture of rat pituitary adenoma
The pituitary tumours were grown in oestrogen-sensi-
tive male four-week-old Fischer 344 rats. Silastic capsu-
les containing 10 mg of diethylstilbestrol (DES, Sigma)
were implanted subcutaneously in the lumbar region.
Eight weeks after the DES implantation the animals
were sacrificed and the pituitary tumours aseptically
removed and placed in Ham’s F-12 medium supple-
mented with 1.176 g/l sodium bicarbonate (Sigma),
100 U/ml penicillin and 100 mg/ml streptomycin solu-
tion (Sigma), 10% heat-inactivated horse serum (Sigma)
and 3% heat-inactivated foetal bovine serum (FBS, Bio-
chrom, KG). The suspension of the pituitary cells was
obtained by mechanical dispersion and subsequent tre-
atment for 30 minutes with collagenase (2 mg/ml) and
hiluronidase (2 mg/ml) at 370C followed by mechanical
agitation. The cells were then triple washed in comple-
te F-10 medium and after the last centrifugation seeded
in fresh medium. The procedure yielded a population
of 95% viable cells.
Experiments
GH3 cells were subjected to the trypsynisation process,
suspended at 106/ml in complete F-10 medium, and
100 ml aliquots of cell suspension (105 cells) were pla-
ced in the wells of the cell culture plates (24 Cell Cultu-
re Cluster Dish, Nuclon Multidishes, Nunc). All the pla-
ted cells were incubated for 12 h (5% CO2, 37°C, 95%
humidity), and after this preincubation period the cells
in the appropriate wells were treated with the following
substances diluted in fresh serum-free medium (100 ml/
well): angiotensin II (Ang II, Sigma) at final concentra-
tions of 10–12, 10–10, 10–8 and 10–6M, angiotensin III (Ang
III, Bachem) at final concentrations of 10–12, 10–10, 10–8
and 10–6M, angiotensin IV (Ang IV, Bachem) at final con-
centrations of 10–12, 10–10, 10–8 and 10–6M, 10–10M Ang II
+ losartan (Merck) at a concentration of 10–8 or 10–7M,
10–10M Ang II + PD123319 (Sigma) at a concentration of
10–8 or 10–7M, losartan at a final concentration of 10–8 or
10–7M, and PD123319 at a final concentration of 10–8 or
10–7M. The same volume of fresh serum-free culture
medium was added to the control wells.
Rat pituitary adenoma cells were plated in 24-well
plates (24 Cell Culture Cluster Dish, Nuclon Multidi-
shes, Nunc) at 2 × 106 cell/well and incubated for 12 h
(5% CO2, 37
0C, 95% humidity). The tested substances
were then added to the appropriate wells: Ang II (Sig-
ma) or Ang III (Bachem) or Ang IV (Bachem) at final
concentrations of 10–12, 10–10, 10–8 and 10–6M. The same
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Figure 1. The influence of angiotensin II (AII) on the secretion of
VEGF in GH3 cell culture after 24 hours of incubation. X ± SEM;
**p < 0.01 vs. C (control)
Rycina 1. Wpływ angiotensyny II (AII) na wydzielanie VEGF
w hodowli komórek GH3 po 24 godzinach inkubacji. X ± SEM;
**p < 0,01 vs. C (kontrola)
Figure 2. The influence of angiotensin III (AIII) on the secretion
of VEGF in GH3 cell culture after 24 hours of incubation. X ± SEM;
*p < 0.05 vs. C (control), **p < 0.01 vs. C, ***p < 0.001 vs. C
Rycina 2. Wpływ angiotensyny III (AIII) na wydzielanie VEGF
w hodowli komórek GH3 po 24 godzinach inkubacji. X ± SEM;
*p < 0,05 vs. C (kontrola), **p < 0,01 vs. C, ***p < 0,001 vs. C
Figure 3. The influence of angiotensin IV (AIV) on the secretion
of VEGF in GH3 cell culture after 24 hours of incubation. X ± SEM;
**p < 0.01 vs. C (control), ***p < 0.001 vs. C
Rycina 3. Wpływ angiotensyny IV (AIV) na wydzielanie VEGF
w hodowli komórek GH3 po 24 godzinach inkubacji. X ± SEM;
**p < 0,01 vs. C (kontrola), ***p < 0,001 vs. C
Figure 4. The influence of angiotensin II (AII) on the secretion
of VEGF in primary rat PRL-secreting adenoma cell culture after
24 hours of incubation. X ± SEM; *p < 0.05 vs. C (control),
**p < 0.01 vs. C, ***p < 0.001 vs. C
Rycina 4. Wpływ angiotensyny II (AII) na wydzielanie VEGF
w pierwotnej hodowli komórkowej guza prolaktynowego szczura
po 24 godzinach inkubacji. X ± SEM; *p < 0,05 vs. C (kontrola),
**p < 0,01 vs. C, ***p < 0,001 vs. C
volume of fresh serum-free culture medium was added
to the control wells.
VEGF determination
All the cells were treated with the substances for 24 ho-
urs. The supernatant was than collected from the wells
and the secreted VEGF isoforms, including the domi-
nating mouse/rat VEGF164, were measured in terms of
pg/ml using specific ELISA assay kits for mouse/rat
VEGF (Mouse VEGF Immunoassay, Quantikine M,
R&D System, USA).
Statistical evaluation
The results are expressed as means ± SD. The normali-
ty of the distribution of the results was examined by
the Student test. Comparisons of individual groups
were evaluated by analysis of variance (ANOVA). Dif-
ferences were considered significant if p < 0.05.
Results
The results of the quantitative analysis and the statisti-
cal evaluation of these results are presented in Figures
1–9. The incubation of GH3 cells with Ang II at concen-
trations of 10–12, 10–10, 10–8 or 10–6M, Ang III at concentra-
tions of 10–12 or 10–10, or Ang IV at a concentration of
10–8M resulted in a significant increase in VEGF secre-
tion, whereas exposure of cells to Ang III or Ang IV at
concentrations of 10–6M led to a significant inhibition of
cytokine release (Fig. 1–3). The exposure of rat pituitary
adenoma cells to Ang II at concentrations of 10–10, 10–8
or 10–6M, Ang III at a concentration of 10–8, or Ang IV at
a concentration 10–8M resulted in a significant elevation
of VEGF concentration in the culture medium (Fig. 4–6).
However, Person’s correlation curve showed a tendency
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Figure 5. The influence of angiotensin III (AIII) on the secretion
of VEGF in primary rat PRL-secreting adenoma cell culture after
24 hours of incubation. X ± SEM; **p < 0.01 vs. C (control)
Rycina 5. Wpływ angiotensyny III (AIII) na wydzielanie VEGF
w pierwotnej hodowli komórkowej guza prolaktynowego szczura
po 24 godzinach inkubacji. X ± SEM; **p < 0,01 vs. C (kontrola)
Figure 7. Correlation between concentrations of angiotensin II
(Ang II) and VEGF levels in primary rat prolactinoma cell culture
after 24 hours of incubation with Ang II.  y = ax + b — simple
regression equation, r — correlation coefficient, p < 0.05
Rycina 7. Korelacja stężeń VEGF i dawek ang II w pierwotnej
hodowli komórkowej guza prolaktynowego szczura poddanej
24-godzinnej inkubacji z ang II. y = ax + b — równanie prostej
regresji, r — współczynnik korelacji, p < 0,05
Figure 6. The influence of angiotensin IV (AIV) on the secretion
of VEGF in primary rat PRL-secreting adenoma cell culture after
24 hours of incubation. X ± SEM; **p<0.01 vs. C (control)
Rycina 6. Wpływ angiotensyny IV (AIV) na wydzielanie VEGF
w pierwotnej hodowli komórkowej guza prolaktynowego szczura
po 24 godzinach inkubacji. X ± SEM; **p<0,01 vs. C (kontrola)
Figure 8. The influence of 24 hours of treatment of GH3 cells
with Ang II (AII, 10–10M), alone or with the combination of Ang II
and specific AT1 receptor antagonist losartan (L), on VEGF
secretion in culture. X ± SEM; *p < 0.05 vs. C (control), **p < 0.05
vs. AII
Rycina 8. Wpływ dodania losartanu (L) do angiotensyny II (AII,
10–10M) na wydzielanie VEGF w hodowli komórkowej linii GH3
po 24 godzinach inkubacji, X ± SEM; *p < 0,05 vs. C (kontrola),
**p < 0,05 vs. AII
for Ang II at concentrations of more than 10–6M to inhi-
bit the VEGF secretion (Fig. 7).
The stimulatory effect of Ang II (10–10M) on VEGF
secretion in GH3 cell culture was cancelled by losartan or
PD123319 in both the concentrations tested. Furthermo-
re, incubation of cells with losartan (10–8 or 10–7M) or
PD123319 (10–7M) alone was followed by a decrease in
VEGF concentration in the culture medium (Fig. 8 and 9).
Discussion
VEGF expression has been shown in the rat, ovine,
mouse and human pituitary. In a normal gland this gly-
coprotein is thought to be predominantly produced by
folliculostellate cells, but its presence in epithelial cells
and co-localisation with anterior pituitary hormones
have also been demonstrated [36]. The studies on ani-
mal models revealed overexpression of VEGF and up-
regulation of VEGF receptor (VEGFR-2) during oestro-
gen-induced pituitary tumour angiogenesis in Fischer
344 rats [37, 38]. In human pituitary adenoma a positi-
ve correlation between cytokine expression and tumo-
ur behaviour has been suggested by some authors [39].
Increasing evidence suggests that a pivotal role is
played by endocrine pituitary tumour cells in the regu-
lation of the angiogenic process essential for tumour
progression. In vitro VEGF was basally secreted by ro-
dent pituitary tumour cells, including folliculostellate
TtT/GF, corticotrope AtT20, gonadotrope aT3-1 and lac-
tosomatotrope GH3, as well as in hormone-inactive,
corticotrope, somatotrope and lactotrope human pitu-
itary adenoma cell cultures [40]. The presence of VEGF
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Figure 9. The influence of 24 hours of treatment of GH3 cells
with Ang II (AII, 10-10M), alone or with the combination of Ang II
and specific AT2 receptor antagonist PD123319 (PD), on VEGF
secretion in culture. X ± SEM; *p < 0.05 vs. C (control), **p < 0.05
vs. AII
Rycina 9. Wpływ dodania PD123319 (PD) do angiotensyny II
(AII, 10-10M) na wydzielanie VEGF w hodowli komórkowej linii
GH3 po 24 godzinach inkubacji, X ± SEM; *p < 0,05 vs. C
(kontrola), **p < 0,05 vs. AII
in secretory granules, the Golgi apparatus and rough
endoplasmic reticulum of GH3 cells has been confirmed
by immunoelectromicroscopy [41]. Lohrer et al. reve-
aled, that VEGF production by TtT/GF cells was au-
gmented in response to pituitary adenylate cyclase po-
lypeptide-38 (PACAP-38), interleukine-6 (IL-6), trans-
forming growth factor-a (TGF-a), insulin-like growth
factor-I (IGF-I) and somatostatin analogue octreotide,
whereas in GH3, AtT20 and aT3-1 cultures basal cyto-
kine levels were not enhanced by any of the stimuli te-
sted. TGF-a, PACAP-38 and 17b-oestradiol increased
VEGF release in human hormone-inactive, somatotrope
and PRL-secreting tumour cell cultures respectively [40].
Since all the factors examined are known to be produced
by pituitary adenoma cells, these results possibly indica-
te complex auto and paracrine regulation of VEGF-de-
pendent angiogenesis during pituitary tumorigenesis.
The present study demonstrates, for the first time
to our knowledge, the involvement of angiotensin pep-
tides in the regulation of the angiogenic activities of the
rat anterior pituitary tumour cells. We revealed that Ang
II, Ang III and Ang IV, at concentrations of 10–12–10–8M,
were able to stimulate VEGF release by both GH3 cells
and by the cultured rat prolactinoma cells. These re-
sults are not surprising in the context of previous obse-
rvations. Ang II was found to enhance in vitro VEGF
secretion in many cell cultures, including human
VSMCs, human mesangial cells, rat heart endothelial
cells and bovine retinal microcapillary pericytes [22–24, 26].
The Ang II derivative Ang IV induced DNA synthesis
and lung endothelial cell proliferation [42]. The pro-
angiogenic effect of exogenous Ang II in pituitary lac-
tosomatotrope tumour cell culture appears to be depen-
dent on both AT1 and AT2 receptors. As we demon-
strated, the specific antagonist of the AT1 receptor lo-
sartan or the specific AT2 receptor blocker PD123319
cancelled the stimulatory action of the peptide on VEGF
secretion by GH3 cells. Furthermore, we also noticed
the inhibitory influences of both AT1 and AT2 receptor
antagonist on the basal VEGF secretion in GH3 cell cul-
ture. We speculate that this phenomenon reflects the
auto-paracrine regulation of the pro-angiogenic activi-
ties of GH3 cells by endogenous angiotensin peptides.
Losartan and PD123319 possibly enable locally produ-
ced angiotensin peptides to stimulate VEGF secretion
via the AT1 and AT2 receptors. Such an explanation is
highly relevant, especially with respect to immunohi-
stochemical and molecular studies demonstrating the
presence of RAS components in GH3 cells [43]. It is no-
teworthy that our results are consistent with the results
of a previous in vivo study. Pawlikowski et al. [35] noti-
ced that an oestrogen-induced increase in vessel area
in the anterior pituitary of DES-treated rats was bloc-
ked by the AT1 receptor antagonist losartan and, to
a lesser degree, by the AT2 receptor antagonist
PD123319.
The essential role of the AT1 receptor in vascular
growth-promoting effects has already been demonstra-
ted by many authors. This receptor subtype mediated
the induction of VEGF receptor KDR expression and
the potentiation of VEGF mitogenic effects in Ang II-
stimulated bovine retinal microcapillary endothelial
cells [25]. The AT1 antagonist losartan negated the sti-
mulatory influences of Ang II on VEGF expression in
human VSMCs, cardiac endothelial cells and renal me-
sangium [22–24]. In vivo it was demonstrated that the
pathway involving the AT1 receptor was engaged in
an increase in vessel density in the cremaster muscle of
rats infused continuously with Ang II and in VEGF-de-
pendent electrically stimulated angiogenesis in skele-
tal muscle [21, 28]. AT1 receptor blockade prevented
retinal neovascularisation in an animal model of reti-
nopathy of prematurity and suppressed hind limb ische-
mia-induced angiogenesis in mice [44, 45]. In contrast,
it has frequently been suggested that the AT2 receptor
exerts an influence that is antagonistic to the AT1 recep-
tor. The anti-angiogenic activity of the AT2 receptor in
hypoxia-induced angiogenesis has been reported [46].
Stoll et al. observed an AT2-dependent anti-proliferati-
ve effect which offsets the growth-promoting action
mediated by AT1 in the coronary endothelial cells [47].
Fujiyama et al. found that the AT1 receptor mediates
endothelial growth factor receptor (EGFR) transactiva-
tion, heparin binding EGF-like growth factor (HB-EGF)
release and subsequent induction of VEGF and angio-
poietin expression in cardiac microvascular endothelial
cells. The AT2 receptor was shown to halt AT1-induced
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EGFR phosphorylation and to attenuate angiogenic
activity by AT1 [48]. Furthermore, AT2 receptor stimu-
lation counteracted VEGF-stimulated endothelial cell
migration and in vitro tube formation in three cell cul-
tures, including human coronary artery, human der-
mal microvascular endothelial cells and the permanent
human endothelial cell line EA.hy926 [49]. This recep-
tor subtype was also responsible for inhibition of AT1-
-induced smooth muscle cell (SMC) migration in AT2
transfected SMCs [50]. AT2 receptor blockade enhan-
ced the pro-angiogenic effect of Ang II in the rat subcu-
taneous sponge granuloma [18].
However, there is increasing evidence that the AT2
receptor may exert growth-promoting and pro-angio-
genic effects. Hence this receptor mediated cardiac and
aortic hypertrophy resulting from pressure overload
and Ang II treatment respectively [51, 52]. Rizkalla at
al. revealed that blockade of both AT1 and AT2 recep-
tors led to a significant decrease in Ang II-induced VEGF
and its receptor KDR expression in the rat kidney and
to concomitant retardation of Ang II-stimulated glome-
rular cell proliferation [53]. In addition the AT1 and AT2
receptors were responsible for increased retinal expres-
sion of VEGF in experimental diabetic rats and in Ang
II treated rats [54]. Our results extend these findings to
effects on VEGF secretion in GH3 cell culture, provi-
ding evidence that both AT1 and AT2 receptor subty-
pes may mediate the stimulatory effect of exogenous
and possibly endogenous angiotensin peptides on
VEGF release by rat pituitary tumour cells. The docu-
mented pro-angiogenic and anti-angiogenic AT2-asso-
ciated effects both indicate that the so-called cell-type-
dependent angiotensin activities are instead determined
by post-receptor events induced in a particular tissue.
A number of recent reports suggest that AT2 and AT1
share, at least in part, common signalling pathways and
may thus participate positively in the regulation of cel-
lular proliferation and angiogenesis [46].
Nevertheles, in addition to the pro-angiogenic ef-
fects of peptides, we noticed that incubation of GH3
cells with Ang III or Ang IV at a concentration of 10–6M
led to a significant decrease in VEGF levels in the cultu-
re medium. Furthermore, Pearson’s correlation curve
showed a tendency for Ang II at concentrations of more
than 10–6M to inhibit VEGF secretion in primary rat pro-
lactinoma culture. These stimulatory and inhibitory effects
on VEGF release may reflect the biphasic influence of
some angiotensin peptides on angiogenesis. A similar
phenomenon was described by Banerjee et al. with re-
spect to oestrogens. The authors observed an increase
in endothelial cell adhesion and proliferation after chro-
nic exposure to nanomolar concentrations of oestradiol
(E2), whereas both cellular adhesion and proliferation
were inhibited by micromolar concentrations of E2 [55].
The present study has not defined the mechanisms whe-
reby angiotensins may inhibit VEGF release. The possi-
ble activation of non-specific mechanisms by supraphy-
siological doses of exogenous peptides should be taken
into consideration. It can also be supposed that the in-
hibitory effect is exerted by Ang II-derived peptides via
non-AT1, non-AT2 receptors such as AT4 or Ang 1–7.
Such a possibility is supported by the observation that
the effect discussed is exerted at a lower concentration
by Ang III and Ang IV in comparison with Ang II. Ho-
wever, this presumption needs to be confirmed in fur-
ther studies.
The results reported here strongly suggest that an
important role is played by RAS in pituitary tumour
angiogenesis, as the overexpression of VEGF seems to
reflect a switch to an angiogenic phenotype, crucial for
the initiation of angiogenesis [56]. Moreover, VEGF may
also stimulate the growth of tumoral cells directly, as
was demonstrated recently in human pituitary adeno-
ma [57, 58] and glioma [59] cells in culture. It is possible
that in the early stage of pituitary tumorigenesis, oestro-
gens or other tumorigenic factors stimulate local or sys-
temic angiotensin peptides to induce VEGF expression
via the AT1 and AT2 receptors. Nevertheless, the same
peptides, overproduced by pituitary adenoma cells, may
lead to suppression of VEGF production and thus con-
tribute to the inhibition of angiogenesis and limitation
of further tumour progression. Such a hypothesis is
possible in relation to the observed biphasic influence
of angiotensins on VEGF release by rat pituitary tumo-
ur cells in culture. This is also probable in the context of
the low vascular density and the usually slow growth
rate of most anterior pituitary tumours.
In summary, Ang II, Ang III and Ang IV affect VEGF
secretion in GH3 and primary rat prolactinoma cell cul-
tures. Both AT1 and AT2 receptors mediate the stimu-
latory actions of exogenous and possibly endogenous
peptides on VEGF release. However, this in vitro study
must be interpreted with caution when extrapolating
these findings to an in vivo context. Further studies, in-
cluding in vivo study and clinical trials, are necessary to
strengthen the hypothesis of the pro-angiogenic effects
of angiotensin peptides in the anterior pituitary and to
establish the potentially beneficial role of AT1 receptor
antagonists in complementary treatment for patients
with PRL-secreting tumours.
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